SALIVARY SPECIFIC IgE TO D1 AND G6 IN PATIENTS WITH RHINITIS WITH OR WITHOUT S. AUREUS COLONIZATION

Globally, allergic rhinitis impacts roughly 25% of children and 40% of adults. Immunoglobulin E (IgE) plays a crucial part in allergic inflammation, with two sources: spontaneously produced IgE, and IgE stemming from reactions to environmental allergens. The damaging effects of S. aureus, as well as Staphylococcal enterotoxins (Ses), have been proven in numerous airway illnesses. As superantigens, Ses generate intense Th2 inflammation, with 70-80% of IgE being locally synthesized. Our study aimed to determine if any correlation existed between local and systemic specific IgE responses in rhinitis patients – both treated and untreated. Furthermore, we sought to pinpoint significant disparities in serum allergy-specific IgE levels between S. aureus positive and negative patients. Results: From 70 patients with a relevant rhinitis history spanning at least two years, we found that in our rhinitis cohort, 36 were sIgE-negative for d1 in blood samples but positive in saliva samples (χ2 = 19.76, α = 0.181), while 25 tested negative for g6 in blood samples but positive for g6 in saliva samples (χ2 = 6.89, α = 0.86). No significant difference emerged between serum allergy-specific IgE levels in S. aureus positive and negative rhinitis patients (χ2 = 0.38). Similar results were noted within the saliva samples. However, mucosal-specific IgE levels were lower among patients receiving active therapy (p < 0.001 for both d1 and g6). Conclusion: There is no correlation between mucosal-specific IgE levels and systemic-specific IgE levels or S. aureus carriers. We observed that salivary-specific IgE levels were lower in patients undergoing active treatment compared to untreated patients.